Clinical Trial Search

Primary: Best Overall Tumor Response Following Administration of CS-7017 in Participants With Advanced or Metastatic Malignancies — 0; 0; 0; 0 Participants

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants

Primary: Incidence of Treatment Emergent Adverse Events — 4; 2; 2; 1 Participants

Primary: Part 2: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Midazolam Alone and in Combination With Risdiplam — 22.6; 25.1 h*ng/mL

Primary: Single-Dose Pharmacokinetic (PK) Parameter: AUClast of Cilofexor — 1236.0; 2450.6; 7712.1; 12458.8 hours*nanogram/millilitre (h*ng/mL)

Primary: Recommended Dose of Plitidepsin in Combination With Bortezomib and Dexamethasone — 5.0 mg/m^2 of plitidepsin

Primary: Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (Cmax) — 12.4; 13.0 ng/mL

Primary: Cmax at Single Dose — 24.4; 68.8; 192; 214 μg/mL

Primary: Time-Weighted Average Change From Baseline up to Day 11 (DAVG11) in Plasma HIV-1 RNA — 4.26; 4.64; 4.42; 4.71 log10 copies/mL — p=<0.001

Primary: Plasma AUX-I and AUX-II Concentrations — NA mmol/L

Primary: Number of Subjects Who Experienced Ocular and Systemic Adverse Events (AEs), Including by Severity — 2; 2; 4; 1 Participants

Primary: Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity as Defined by the Study Protocol — 10; 10 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in Part A and Part C — 0; 0; 0 Participants

Primary: Dose-escalation Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0 Participants

Primary: Number of Subjects Reporting Adverse Events — 38; 22 Participants